Skip to main content
. 2022 Mar 5;14(3):572. doi: 10.3390/pharmaceutics14030572

Figure 5.

Figure 5

Summary of (a) logRDTE% (n = 24), (b) logRDTP% (n = 14), (c) B%IN/IV (n = 28), and (d) RB% (n = 32) for SLN and NLC-based formulation.